Grabenstetter Anne, Brogi Edi, Zhang Hong, Razavi Pedram, Reis-Filho Jorge S, VanZee Kimberly J, Norton Larry, Wen Hannah Y
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
NPJ Breast Cancer. 2022 Aug 11;8(1):93. doi: 10.1038/s41523-022-00469-z.
Breast adenoid cystic carcinoma (AdCC) is a rare subtype of triple negative breast cancer. Two morphologic variants are described, namely classic AdCC (C-AdCC) and solid basaloid (SB-AdCC). Recent studies have shown that the SB-AdCC variant has significantly worse prognosis than C-AdCC. Due to the rarity of SB-AdCC, no standard recommendations are available for its management. Data on the use and benefit of chemotherapy in patients with SB-AdCC are sparse and the response to neoadjuvant chemotherapy has not been reported. We present the clinical and pathologic findings of a patient with SB-AdCC treated with neoadjuvant chemotherapy who achieved a remarkable pathologic response.
乳腺腺样囊性癌（AdCC）是三阴性乳腺癌的一种罕见亚型。描述了两种形态学变体，即经典AdCC（C-AdCC）和实体基底样型（SB-AdCC）。最近的研究表明，SB-AdCC变体的预后明显比C-AdCC差。由于SB-AdCC罕见，尚无针对其治疗的标准建议。关于SB-AdCC患者化疗的使用和益处的数据稀少，且尚未有新辅助化疗反应的报道。我们展示了一名接受新辅助化疗的SB-AdCC患者的临床和病理结果，该患者取得了显著的病理反应。
